<SEC-DOCUMENT>0000950103-22-019261.txt : 20221107
<SEC-HEADER>0000950103-22-019261.hdr.sgml : 20221107
<ACCEPTANCE-DATETIME>20221107090514
ACCESSION NUMBER:		0000950103-22-019261
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221107
FILED AS OF DATE:		20221107
DATE AS OF CHANGE:		20221107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		221363971

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp183926_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of November 2022.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<HR NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39071</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Biop&ocirc;le</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Route de la Corniche 3B</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1066 Epalinges</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Switzerland</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 66%; font: 8pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9746;</P>
</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 14%">
</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: November 7, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated November 7, 2022</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp183926_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="image_011.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics to Participate in the Jefferies
London Healthcare Conference</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>LAUSANNE, Switzerland, November 7, 2022</B>
&ndash; ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat
at the Jefferies London Healthcare Conference on Tuesday, November 15<SUP>th</SUP> at 9:45 a.m. GMT.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A live webcast of the presentation will be available
via the Events &amp; Presentations page in the Investors section of ADC Therapeutics&rsquo; website, <FONT STYLE="color: Blue"><U>ir.adctherapeutics.com</U></FONT>.
A replay of the webcast will be available for approximately 30 days.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About ADC Therapeutics</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).&nbsp;The
Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies
and solid tumors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ADC Therapeutics&rsquo; CD19-directed ADC ZYNLONTA<SUP>&reg;
</SUP>(loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma
after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine)
is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various
advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ADC Therapeutics is based in Lausanne (Biop&ocirc;le),
Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit <FONT STYLE="color: Blue"><U>https://adctherapeutics.com/
</U></FONT>and follow the Company on&nbsp;<FONT STYLE="color: Blue"><U>Twitter</U></FONT>&nbsp;and&nbsp;<FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ZYNLONTA<SUP>&reg;</SUP> is a registered trademark of ADC Therapeutics
SA.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>Investors</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Eugenia Litz&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>Eugenia.Litz@adctherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">+44 7879 627205</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Amanda Loshbaugh&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">ADC Therapeutics</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue"><U>Amanda.Loshbaugh@adctherapeutics.com</U></FONT><U>&nbsp;</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">+1 917-288-7023</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>Media</B><BR>
Mary Ann Ondish<BR>
ADC Therapeutics<BR>
<FONT STYLE="color: Blue"><U>Maryann.Ondish@adctherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">+1 914-552-4625</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" != *<# 2(  A$! Q$!_\0
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MX9&W@_@<UW?A_P"*$%RZ6^LQ"!SP)X_N?B.HK USX9ZGIL3SV4BWL*\E5&'
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&1_UVT/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
